Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 12/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 11/20 | 0.48 |
| ▸ | CACNA1I | Q9P0X4 | 11/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30796164 | 1.00 | CACNA1H (0.48) | CACNA1HCACNA1GCACNA1IALDH1A1KMT2A | |
| SCHEMBL1789193 | 0.89 | MEN1 (0.45) | CACNA1GCACNA1IALDH1A1KMT2ACNR2 | |
| SCHEMBL30814174 | 0.89 | MEN1 (0.45) | CACNA1GCACNA1IALDH1A1KMT2ACNR2 | |
| SCHEMBL30795856 | 0.87 | LMNA (0.52) | CNR2LMNAPOLB | |
| SCHEMBL1786577 | 0.87 | LMNA (0.52) | CNR2LMNAPOLB | |
| SCHEMBL30795173 | 0.86 | KDM4E (0.49) | CACNA1HCACNA1GCACNA1IALDH1A1KMT2A | |
| SCHEMBL1788526 | 0.86 | KDM4E (0.49) | CACNA1HCACNA1GCACNA1IALDH1A1KMT2A | |
| SCHEMBL30796432 | 0.85 | PTGS2 (0.43) | ALDH1A1KMT2ALMNAPOLB | |
| SCHEMBL1786193 | 0.85 | PTGS2 (0.43) | ALDH1A1KMT2ALMNAPOLB | |
| SCHEMBL1788705 | 0.82 | RIOK2 (0.47) | ALDH1A1KMT2ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629143-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2014-01-14 | — | — | US | claimed |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | claimed |
| US-8629143-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2014-01-14 | — | — | US | disclosed |
| EP-2504317-A1 | POTASSIUM CHANNEL MODULATORS | Abbott Laboratories (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011066168-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-06-03 | — | — | WO | disclosed |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNQ3 | CACNA1H 70/4885CACNA1G 60/4885CACNA1I 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.